Related Experiment Video

Updated: Jun 5, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9

Brandon Ason1, Samnang Tep, Harry R Davis

  • 1Sirna Therapeutics/Merck & Co. Inc, San Francisco, CA 94158, USA. brandon_ason@merck.com

Journal of Lipid Research
|January 26, 2011
PubMed

Insights

PCSK9 inhibition combined with statins and ezetimibe significantly lowers LDL-cholesterol and triglycerides. This approach enhances the efficacy of current hypercholesterolemia treatments.

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Molecular Biology

Background:

  • Elevated LDL-cholesterol (LDL-c) is a major risk factor for cardiovascular disease.
  • Statins and ezetimibe lower LDL-c but can increase PCSK9, potentially limiting their effectiveness.
  • PCSK9 regulates LDL receptor degradation, influencing circulating LDL-c levels.

Purpose of the Study:

  • To investigate if inhibiting PCSK9 can enhance the LDL-c lowering effects of statins and ezetimibe.
  • To evaluate the combined efficacy of PCSK9 knockdown with ezetimibe and rosuvastatin in a mouse model.

Main Methods:

  • Utilized small interfering RNAs (siRNAs) to knock down Pcsk9 in a mouse model.
  • Administered ezetimibe, rosuvastatin, and a combination of both.
  • Assessed serum lipid profiles, including LDL-c, non-HDL, APOB, and triglycerides.

Main Results:

  • Ezetimibe, rosuvastatin, and their combination lowered serum cholesterol but upregulated Pcsk9 and Srebp-2 pathways.
  • PCSK9 knockdown significantly amplified the cholesterol-lowering effects of both monotherapy and combination treatments.
  • Combined rosuvastatin, ezetimibe, and Pcsk9 siRNA treatment markedly reduced serum APOB and triglyceride levels.

Conclusions:

  • PCSK9 inhibition potentiates the LDL-c reduction achieved by statins and ezetimibe.
  • Combination therapy including PCSK9 inhibition offers a promising strategy for greater lipid-lowering.
  • This approach may lead to improved cardiovascular risk reduction in hypercholesterolemia patients.

More Related Videos

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK908:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...